Your browser is no longer supported. Please, upgrade your browser.
Settings
BMY Bristol-Myers Squibb Company daily Stock Chart
BMY [NYSE]
Bristol-Myers Squibb Company
IndexS&P 500 P/E30.25 EPS (ttm)2.01 Insider Own0.10% Shs Outstand1.66B Perf Week2.66%
Market Cap100.81B Forward P/E15.82 EPS next Y3.85 Insider Trans0.29% Shs Float1.63B Perf Month7.69%
Income3.30B PEG2.66 EPS next Q0.89 Inst Own73.60% Short Float0.80% Perf Quarter15.52%
Sales21.60B P/S4.67 EPS this Y-10.90% Inst Trans0.18% Short Ratio2.01 Perf Half Y-11.70%
Book/sh7.54 P/B8.08 EPS next Y6.47% ROA1.10% Target Price59.44 Perf Year7.26%
Cash/sh3.67 P/C16.59 EPS next 5Y11.38% ROE2.90% 52W Range49.96 - 70.05 Perf YTD-0.64%
Dividend1.60 P/FCF66.19 EPS past 5Y15.30% ROI20.20% 52W High-13.08% Beta1.01
Dividend %2.63% Quick Ratio1.30 Sales past 5Y3.30% Gross Margin70.50% 52W Low21.88% ATR1.11
Employees23700 Current Ratio1.40 Sales Q/Q10.90% Oper. Margin20.90% RSI (14)66.21 Volatility1.59% 2.25%
OptionableYes Debt/Eq0.60 EPS Q/Q-59.30% Profit Margin1.70% Rel Volume1.35 Prev Close61.11
ShortableYes LT Debt/Eq0.46 EarningsJul 26 BMO Payout684.10% Avg Volume6.50M Price60.89
Recom2.50 SMA203.33% SMA507.59% SMA2002.42% Volume8,798,772 Change-0.36%
Aug-08-18Upgrade Atlantic Equities Underweight → Neutral
Apr-17-18Downgrade Morgan Stanley Overweight → Equal-Weight
Apr-12-18Reiterated Citigroup Buy $78 → $70
Mar-20-18Reiterated JP Morgan Overweight $70 → $75
Feb-15-18Upgrade Morgan Stanley Equal-Weight → Overweight
Oct-30-17Upgrade SunTrust Hold → Buy
Oct-16-17Downgrade Jefferies Buy → Hold
Sep-12-17Downgrade Hilliard Lyons Long-term Buy → Neutral
Dec-19-16Upgrade Jefferies Hold → Buy
Oct-28-16Reiterated Deutsche Bank Hold $59 → $52
Sep-09-16Reiterated Barclays Equal Weight $75 → $65
Aug-11-16Downgrade Berenberg Buy → Hold
Aug-08-16Reiterated Deutsche Bank Hold $68 → $62
Aug-08-16Downgrade Credit Suisse Outperform → Neutral $63
Aug-05-16Downgrade Morgan Stanley Overweight → Equal-Weight
May-23-16Initiated Hilliard Lyons Neutral
Apr-29-16Reiterated UBS Buy $73 → $80
Apr-29-16Reiterated Barclays Equal Weight $70 → $75
Apr-06-16Initiated Societe Generale Sell $48
Jan-22-16Upgrade Berenberg Hold → Buy
Aug-17-18 08:03AM  FDA approves Bristol-Myers' Opdivo for small cell lung cancer Reuters
07:09AM  Bristol-Myers wins FDA approval for Opdivo as treatment for small cell lung cancer MarketWatch
06:59AM  U.S. Food and Drug Administration Approves Opdivo® (nivolumab) as the First New Medication in Nearly 20 Years for Certain Patients with Previously Treated Small Cell Lung Cancer Business Wire
Aug-16-18 09:37AM  The Daily Biotech Pulse: No Anxiety For Biohaven, Strongbridge's About-Face, Bristol-Myers Squibb's FDA Wait Benzinga
Aug-15-18 04:21PM  Heat Biologics Stock Is a Worthwhile, Speculative Bet InvestorPlace
02:58PM  The stocks you wanted to know about today CNBC Videos
Aug-14-18 10:06AM  5 Top-Ranked S&P 500 Stocks to Buy on Market Dip Zacks
06:52AM  Zacks.com featured highlights include: United States Cellular, Molina Healthcare, Archer Daniels, Bristol-Myers and Callaway Golf Zacks
06:02AM  Better Buy: GlaxoSmithKline plc vs. Bristol-Myers Squibb Motley Fool
Aug-13-18 08:13AM  Pick These 5 Stocks With Remarkable Relative Price Strength Zacks
07:38AM  The Zacks Analyst Blog Highlights: Novo Nordisk, J&J, Allergan, Editas, AstraZeneca, Merck and Bristol-Myers Zacks
Aug-12-18 04:52PM  The Week Ahead In Biotech: Conferences, PDUFA Dates, Earnings And IPOs Benzinga
Aug-10-18 05:39PM  Edited Transcript of BMY earnings conference call or presentation 26-Jul-18 2:30pm GMT Thomson Reuters StreetEvents
Aug-09-18 09:52AM  Nektar (NKTR) Q2 Earnings In Line, Product Sales Down Y/Y Zacks
Aug-08-18 08:10AM  Report: Developing Opportunities within Cytosorbents, Nasdaq, Mastercard, Maxim Integrated Products, Bristol-Myers Squibb, and Equity Lifestyle Properties Future Expectations, Projections Moving into 2018 GlobeNewswire
Aug-07-18 09:50AM  Q2 Earnings Drive Pharma ETFs Higher Zacks
09:30AM  BMY vs. NVO: Which Stock Is the Better Value Option? Zacks
Aug-06-18 09:09AM  The Zacks Analyst Blog Highlights: Pfizer, Bristol-Myers, Sanofi, Glaxo and Novartis Zacks
Aug-03-18 11:23AM  Pharma Stock Roundup: PFE Dominates Headlines, BMY Drug Gets EU Approval Zacks
Aug-02-18 02:10PM  Moody's: US drug makers face heightened pricing pressure as regulatory risks pick up steam Moody's
12:50PM  Here's Why Exelixis Stock Jumped Higher Today Motley Fool
Aug-01-18 05:24PM  The opioid drug that addicts don't like could be approved next spring American City Business Journals
Jul-31-18 08:20AM  Today's Research Reports on Trending Tickers: Bristol-Myers Squibb and Allergan ACCESSWIRE
06:59AM  European Commission Approves Bristol-Myers Squibbs Opdivo (nivolumab) for the Adjuvant Treatment of Adult Patients with Melanoma with Involvement of Lymph Nodes or Metastatic Disease Who Have Undergone Complete Resection Business Wire
Jul-27-18 12:16PM  Merck profit beats, but Keytruda sales fail to impress Reuters
11:01AM  Why Bristol-Myers Squibb (BMY) is a Top Dividend Stock Zacks
07:48AM  [$$] Merck overtakes rival on immunotherapy drug sales Financial Times
Jul-26-18 12:52PM  Bristol-Myers cancer ruling hits shares after strong earnings Reuters
11:11AM  Bristol-Myers (BMY) Beats on Q2 Earnings, Raises Outlook Zacks
10:59AM  Bristol-Myers to get negative CHMP opinion on renal cancer drugs Reuters
10:30AM  Bristol-Myers profit tops Street view, raises full-year forecast Reuters
09:10AM  Bristol-Myers Squibb (BMY) Surpasses Q2 Earnings and Revenue Estimates Zacks
07:40AM  Bristol-Myers: 2Q Earnings Snapshot Associated Press
07:36AM  Bristol-Myers shares lift on Q2 profit, revenue beats MarketWatch
07:19AM  Bristol-Myers (BMY) Q2 Earnings Beat Estimates Zacks
07:01AM  Bristol-Myers Drops After Cancer Drug Combo Rejected in Europe Bloomberg
06:59AM  Bristol-Myers Squibb Reports Second Quarter Financial Results Business Wire
06:59AM  Bristol-Myers Q2 earnings rise, full-year forecast up on strong sales Reuters
Jul-25-18 02:50PM  Q2 Earnings Preview For Bristol-Myers Squibb Benzinga
10:27AM  Drug Stocks to Report Earnings on Jul 26: AMGN, ALXN & More Zacks
08:00AM  Today's Research Reports on Trending Tickers: Bristol-Myers Squibb and Eli Lilly and Company ACCESSWIRE
Jul-24-18 07:00AM  Bristol-Myers Squibb and Tsinghua University Announce Collaboration to Accelerate Early Research into Potential Therapies for Autoimmune Diseases and Cancer Business Wire
06:00AM  Bristol-Myers Stock May Rebound 8% Short Term Investopedia
Jul-23-18 10:59AM  Is a Beat in Store for Bristol-Myers (BMY) in Q2 Earnings? Zacks
08:30AM  Bristol-Myers Squibb Announces Departure of Chief Commercial Officer Business Wire
Jul-20-18 11:26AM  [$$] IFM Therapeutics Launches Subsidiary With $31 Million Series A The Wall Street Journal
Jul-19-18 11:51AM  Value investors Nygren's stock buys: Hilton, Gartner and ... CNBC Videos
07:00AM  Bristol-Myers Squibb and Gritstone Oncology Announce Clinical Research Collaboration to Evaluate Novel Immunotherapy Approach in Advanced Solid Tumors Business Wire
Jul-13-18 08:50AM  Pharma Stock Roundup: PFE to Split Into 3 Units, J&J to Pay $4.7B in Talc Lawsuit Zacks
Jul-12-18 06:03PM  3 Pharma Stocks Goldman Sachs Sees as Buys TheStreet.com
09:21AM  Bristol-Myers' Combo Drugs Get FDA Nod for Colorectal Cancer Zacks
Jul-11-18 03:11PM  Russian Drugmaker Granted License to Produce Celgene Copycat Fortune
07:05AM  Moffitt licensing deal could provide new approach for some cancer patients American City Business Journals
06:59AM  Bristol-Myers Squibbs Opdivo® (nivolumab) + Low-Dose Yervoy® (ipilimumab) is the First Immuno-Oncology Combination Approved for MSI-H/dMMR mCRC Patients Who Progressed Following Treatment with a Fluoropyrimidine, Oxaliplatin and... Business Wire
Jul-09-18 05:37PM  Could P&G bid for Bristol-Myers Squibb unit? American City Business Journals
01:26PM  Only Immuno-Oncology Combination Therapy Approved by Health Canada as First-Line Treatment for Advanced or Metastatic Renal Cell Carcinoma CNW Group
07:10AM  Wired News - The European Commission Approves Expanded Indication for Bristol-Myers Squibb's Sprycel ACCESSWIRE
Jul-08-18 07:16PM  The Week Ahead In Biotech: Conferences, PDUFA Dates And Clinical Trials Benzinga
Jul-06-18 07:41AM  Bristol-Myers' Sprycel Gets EC Approval for Label Expansion Zacks
Jul-05-18 12:03PM  Pfizer's Stock Ready for a 10% Rebound Investopedia
11:46AM  Go Long Pfizer Stock Its an Easy Pill to Swallow InvestorPlace
06:59AM  European Commission Approves Expanded Indication for Sprycel (dasatinib) to Include Treatment of Children with Philadelphia Chromosome-Positive Chronic Myeloid Leukemia in Chronic Phase Business Wire
Jul-03-18 06:01AM  The 5 Biggest Blockbuster Drugs of 2024, and the Companies Poised to Profit From Them Motley Fool
Jun-29-18 07:54AM  Bristol-Myers Squibb Receives Positive CHMP Opinion Recommending Approval of Opdivo (nivolumab) for the Adjuvant Treatment of Adult Patients with Melanoma Business Wire
Jun-26-18 02:16PM  Bristol-Myers Stock May Rebound 9% Short Term Investopedia
07:30AM  Wired News - FDA Accepts Bristol-Myers Squibbs Application for Opdivo Plus Low-Dose Yervoy for First-Line Non-Small Cell Lung Cancer Treatment ACCESSWIRE
06:00AM  13 Companies With Attractive, Low-Risk Dividends Morningstar
Jun-22-18 04:56PM  Bristol-Myers' BLA for Opdivo Label Expansion Accepted by FDA Zacks
09:52AM  Pharma Stock Roundup: PTCT Unveils Promising Data, RHHBY to Acquire Rest of FMI Zacks
08:51AM  Benzinga's Daily Biotech Pulse: FDA Greenlights Tandem Diabetes' Insulin Pump, More IPOs On Tap Benzinga
Jun-21-18 04:15PM  U.S. Food and Drug Administration (FDA) Accepts Application for Opdivo Plus Low-Dose Yervoy for Treatment of First-Line Non-Small Cell Lung Cancer in Patients with Tumor Mutational Burden 10 mut/Mb Business Wire
08:49AM  What You Must Know About Bristol-Myers Squibb Companys (NYSE:BMY) 7.31% ROE Simply Wall St.
07:28AM  Initiating Free Research Reports on Bristol-Myers Squibb and Three Other Drug Makers Equities ACCESSWIRE
Jun-20-18 09:02AM  NYSE Pharma And Biotech Dividend Stock Picks Simply Wall St.
06:59AM  Dallas Cowboys Quarterback Dak Prescott, Modern Family Star Eric Stonestreet and Actress Tia Mowry Call on Americans to Rise Up Against Cancer Through Ready. Raise. Rise. Business Wire
Jun-18-18 06:23PM  Bristol-Myers Posts Data on Empliciti, China Approves Opdivo Zacks
03:00PM  Eight Stocks That Are Poised to Change Direction TheStreet.com
06:00AM  5 Drug Stocks With Fat Payouts Investopedia
Jun-17-18 06:30AM  Empliciti (elotuzumab) Plus Pomalidomide and Low-Dose Dexamethasone Reduces the Risk of Disease Progression by 46% Versus Pomalidomide/Dexamethasone Alone in Patients with Relapsed or Refractory Multiple Myeloma Business Wire
Jun-15-18 02:31PM  Cash for NASH: 2 Top Biotech Takeover Targets and 3 Potential Buyers Motley Fool
08:32AM  China National Drug Administration Approves Countrys First Immuno-Oncology Agent, Opdivo (nivolumab injection), for Previously Treated Non-Small Cell Lung Cancer (NSCLC) Business Wire
Jun-14-18 04:30PM  Bristol-Myers Squibb Announces Dividend Business Wire
Jun-13-18 06:00AM  Bristol-Myers Squibb to Present New Research Findings on the Treatment of Patients with Early Rheumatoid Arthritis at the Annual European Congress of Rheumatology (EULAR 2018) Business Wire
Jun-12-18 05:32PM  Does Bristol-Myers Squibb Companys (NYSE:BMY) PE Ratio Signal A Selling Opportunity? Simply Wall St.
Jun-11-18 04:45PM  Bristol-Myers Squibb to Take Part in Goldman Sachs 39th Annual Global Healthcare Conference Business Wire
09:29AM  Fred Hutch leases iconic Lake Union Steam Plant facility American City Business Journals
09:08AM  The Zacks Analyst Blog Highlights: Bristol Myers, Merck, Roche, Lilly and AbbVie Zacks
Jun-08-18 10:27AM  Pharma Stock Roundup: MRK Impresses at ASCO, LLY Gets FDA Nod for Olumiant Zacks
Jun-07-18 09:09PM  Why Nektar Therapeutics Stock Stumbled 11.8% Today Motley Fool
06:59AM  Bristol-Myers Squibb to Announce Results for Second Quarter 2018 on July 26 Business Wire
Jun-06-18 04:15PM  Here's Why Nektar Therapeutics Jumped as Much as 17% Today Motley Fool
08:29AM  ASCO Ends: Winners & Losers at the Key Cancer Research Event Zacks
Jun-05-18 11:00AM  Nektar Therapeutics Stock Is a Buy After a Major Market Misread InvestorPlace
08:42AM  Nektar (NKTR) and Bristol-Myers Present Data on Cancer Study Zacks
08:13AM  Do Nektars disappointing clinical trial results invalidate $2 billion Bristol-Myers deal? MarketWatch
06:08AM  Bristol-Myers (BMY) Reports Data from CheckMate-214 Study Zacks
Jun-04-18 05:14PM  Nektar Therapeutics Just Lost More Than $6 Billion in Value Because of One Drug TheStreet.com
04:40PM  Is Nektar Therapeutics Stock a Bargain Now? Motley Fool
03:56PM  $15 billion biotech stock loses more than 40% of its value after skin cancer drug study falls short CNBC
03:32PM  Merck emerges as key winner at ASCO conference CNBC Videos
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, and distributes biopharmaceutical products worldwide. The company offers drugs in various therapeutic classes, such as oncology; cardiovascular; immunoscience; and virology, including human immunodeficiency virus (HIV) infection. Its products include Opdivo, a biological product for anti-cancer indications; Eliquis, an oral inhibitor targeted at stroke prevention in atrial fibrillation and the prevention and treatment of venous thromboembolic disorders; Orencia, a biological product that targets adult patients with active rheumatoid arthritis and prostate-specific antigen; and Sprycel, a tyrosine kinase inhibitor for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia. The company's products also comprise Yervoy, a monoclonal antibody for the treatment of adults and pediatric patients with unresectable or metastatic melanoma; Empliciti, a human monoclonal antibody for the treatment of multiple myeloma; Baraclude, a potent and selective inhibitor of the hepatitis B virus; Sustiva, a non-nucleoside reverse transcriptase inhibitor for HIV and bulk efavirenz; Reyataz, a protease inhibitor for the treatment of HIV and combination therapy Evotaz; Daklinza, an oral small molecule NS5A replication complex inhibitor for the treatment of hepatitis C virus (HCV); and Sunvepra, an oral small molecule for the treatment of HCV. It sells products to wholesalers, retail pharmacies, hospitals, government entities and the medical profession. Bristol-Myers Squibb Company has a research partnership with Sirenas; and a collaboration agreement with Nektar Therapeutics, Illumina, Inc., Janssen Pharmaceuticals, Inc., and Advantagene, Inc., as well as Tsinghua University. The company was formerly known as Bristol-Myers Company and changed its name to Bristol-Myers Squibb Company in 1989. Bristol-Myers Squibb Company was founded in 1887 and is headquartered in New York, New York.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Gordon MurdoEVP, Chief Commercial OfficerAug 01Option Exercise0.001,510050,168Aug 03 05:05 PM
Biondi PaulSVP, Head of Strategy & BDJul 01Option Exercise0.001,46101,461Jul 03 09:24 PM
Caforio GiovanniChairman and CEOMay 05Option Exercise0.008,0400292,822May 08 05:05 PM
Paliwal Dinesh CDirectorApr 30Buy52.404,770249,9488,027May 02 04:05 PM
Lynch Thomas J. Jr.EVP & Chief Scientific OfficerApr 03Option Exercise0.0012,367018,267Apr 05 04:37 PM
Schmukler Louis SPres., Global Mfg. & SupplyMar 10Option Exercise0.0034,681053,132Mar 13 04:57 PM
Santiago Karen MurphyControllerMar 10Option Exercise0.004,40704,456Mar 13 04:55 PM
JUDGE ANN POWELLSVP, Global Human ResourcesMar 10Option Exercise0.0036,044075,370Mar 13 04:56 PM
von Autenried PaulSVP, Enterp. Services & CIOMar 10Option Exercise0.0031,2750136,441Mar 13 04:54 PM
Elicker John ESVP, Public Affairs & IRMar 10Option Exercise0.0020,043086,932Mar 13 04:56 PM
Caforio GiovanniChairman and CEOMar 10Option Exercise0.00219,2110333,970Mar 13 04:56 PM
Gordon MurdoEVP, Chief Commercial OfficerMar 10Option Exercise0.0039,235062,028Mar 13 04:55 PM
Bancroft Charles AEVP & Chief Financial OfficerMar 10Option Exercise0.0091,3180363,739Mar 13 04:53 PM
LEUNG SANDRAEVP, General CounselMar 10Option Exercise0.0068,8960488,677Mar 13 04:54 PM
Bancroft Charles AEVP & Chief Financial OfficerFeb 23Option Exercise22.1437,460829,364302,348Feb 27 04:45 PM
Samuels Theodore R. IIDirectorDec 15Buy62.304,000249,18722,000Dec 18 04:21 PM
Lynch Thomas J. Jr.EVP & Chief Scientific OfficerDec 12Sale63.245,300335,1729,251Dec 13 05:31 PM
LEUNG SANDRAEVP, General CounselDec 04Option Exercise22.14156,5823,466,725584,373Dec 05 06:15 PM
LEUNG SANDRAEVP, General CounselDec 04Sale63.37156,5829,922,601427,791Dec 05 06:15 PM
Bancroft Charles AEVP & Chief Financial OfficerDec 02Option Exercise0.006,4010267,770Dec 05 06:15 PM
Elicker John ESVP, Public Affairs & IRNov 01Option Exercise0.00494068,166Nov 03 04:32 PM
Caldarella Joseph CSVP & ControllerSep 06Sale60.009,340560,40046,297Sep 08 04:31 PM
Nielsen AnneChief Compliance & Ethics OffSep 03Option Exercise0.001,594038,811Sep 06 04:46 PM